Findings of the TRUE-AHF trial are different from those of the RELAX-AHF trial, where treatment with the serelaxin led to decreases in NT-proBNP levels as well as decreased rates of in-hospital worsening of heart failure followed by reductions in cardiovascular mortality [19]. The gene discussed is NPPB; the disease is heart failure.